In a combinatorial study, anti-PD-1 mAbs, used either as single-agent or in combination with anti-CTLA-4 mAbs have been tested on patients with melanoma and non-small cell lung cancer (NSCLC) and IL-8 levels were monitored [206]. This evidence concerns the gene CXCL8 and non-small cell lung carcinoma.